Thank you for sharing!

Your article was successfully shared with the contacts you provided.

As we’ve noted before, Mississippi AG Jim Hood isn’t shy about filing lawsuits. But so far, his aggressive posture against Eli Lilly in a case involving the controversial anti-psychotic Zyprexa hasn’t paid off. In a 116-page decision issued Tuesday (available here, via Pharmalot) Brooklyn federal district court Judge Jack Weinstein knocked out most of Hood’s suit, which sought to recover billions of dollars that Mississippi’s Medicaid system paid for Zyprexa. Hood’s suit alleged that Lilly improperly marketed the drug for off-label uses and failed to disclose its side effects. Mississippi now finds itself in the uncomfortable position of being one of very few states that hasn’t collected on Zyprexa-related claims against Lilly. Like several other states, Mississippi opted not to participate in Lilly’s record-setting $1.4 billion False Claims Act settlement last January because it wanted to pursue its own litigation against Lilly. But most of those other states have since settled. Last fall, Lilly reached a $62 million deal with 32 states, leaving only 12 states with pending claims. And of those 12, according to LegalNewsline, most have reached official or tentative settlements, including Connecticut ($25.1 million); West Virginia ($22 million-plus); Idaho ($13 million); Utah ($24 million); and South Carolina ($45 million). Mississippi continued litigating, though, with claims that Weinstein (who was assigned jurisdiction over most of the federal Zyprexa litigation by the Judicial Panel on Multidistrict Litigation) criticized in his summary judgment ruling. “If allowed to proceed in their entirety, the state’s claims could result in serious harm or bankruptcy for this defendant and the pharmaceutical industry generally,” he wrote. “For the legal system to be used for this slash-and-burn style of litigation would arguably constitute an abuse of the legal process. Constitutional, statutory, and common law rights of those injured to seek relief from the courts must be recognized. But courts cannot be used as an engine of an industry’s destruction.” Weinstein’s ruling left standing only Mississippi’s claims based on the difference between the market price of Zyprexa and the value the state received. According to Weinstein, that issue is before the 2nd U.S. Circuit Court of Appeals. We left messages with both the Mississippi AG’s office and its outside counsel, Mike Perrin of Bailey Perrin Bailey, but didn’t hear back. Lilly, which told LegalNewline it was “pleased” with the decision, is represented by Pepper Hamilton attorneys Andrew Rogoff, Matthew Hamilton, Nina Gussack, Allan Andrew Thoen, Samuel Abate Jr., John Brenner and George Lehner.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]


ALM Legal Publication Newsletters

Sign Up Today and Never Miss Another Story.

As part of your digital membership, you can sign up for an unlimited number of a wide range of complimentary newsletters. Visit your My Account page to make your selections. Get the timely legal news and critical analysis you cannot afford to miss. Tailored just for you. In your inbox. Every day.

Copyright © 2021 ALM Media Properties, LLC. All Rights Reserved.